文献速递肝肾功能剂量调整药物不良反应与药物警戒治疗药物监测与药物基因组学

哌拉西林-他唑巴坦联合替考拉宁与联合万古霉素的急性肾损伤风险比较:系统评价与荟萃分析

Comparative Risk of Acute Kidney Injury with Piperacillin-Tazobactam Plus Teicoplanin Versus Piperacillin-Tazobactam Plus Vancomycin: A Systematic Review and Meta-Analysis.
PubMed 文献 · Drug Saf · 2025-09-12

该系统评价与荟萃分析纳入5项队列研究共908例住院患者,比较哌拉西林-他唑巴坦联合替考拉宁(TZP-TEI)与联合万古霉素(TZP-VAN)的肾安全性。结果显示TZP-TEI组急性肾损伤(AKI)发生率显著低于TZP-VAN组(OR 0.52;95%CI 0.30-0.89;p=0.02;I2=51%),而AKI恢复和30天全因死亡率无显著差异。

要点

  • TZP-TEI较TZP-VAN显著降低AKI发生率(OR 0.52;95%CI 0.30-0.89)。
  • 两组AKI恢复(OR 0.68;95%CI 0.41-1.12)和30天全因死亡率(OR 1.34;95%CI 0.77-2.32)无显著差异。
  • 亚组分析显示不同AKI严重程度分期方向一致,但需进一步研究验证。

核心结论

  • TZP-TEI组合的AKI发生率显著低于TZP-VAN组合。
  • 两组在AKI恢复和30天全因死亡率方面无统计学显著差异。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Scopus和Cochrane Central数据库。
  • 纳入5项比较TZP-TEI与TZP-VAN的队列研究,共908例住院患者,其中4项采用倾向评分匹配(PSM)。
  • 纳入研究报告年龄范围为56.8至79岁。

主要发现

  • TZP-TEI组AKI发生率显著低于TZP-VAN组(OR 0.52;95%CI 0.30-0.89;p=0.02;I2=51%)。
  • AKI恢复率两组无显著差异(OR 0.68;95%CI 0.41-1.12;p=0.13;I2=0%)。
  • 30天全因死亡率两组无显著差异(OR 1.34;95%CI 0.77-2.32;p=0.30;I2=0%)。
  • 按AKI严重程度(KDIGO 1-3期或RIFLE标准)分层亚组分析方向一致,PSM和非PSM队列内均无显著差异。

关键数值与推荐

  • 主要结局AKI采用KDIGO或RIFLE标准定义。
  • TZP-TEI较TZP-VAN的AKI风险OR为0.52(95%CI 0.30-0.89;p=0.02;I2=51%)。
  • AKI恢复OR为0.68(95%CI 0.41-1.12;p=0.13;I2=0%)。
  • 30天全因死亡率OR为1.34(95%CI 0.77-2.32;p=0.30;I2=0%)。

临床怎么用

  • 对于需要哌拉西林-他唑巴坦联合抗MRSA覆盖的住院患者,可考虑替考拉宁替代万古霉素以降低AKI风险。
  • 替考拉宁在TZP-TEI组合中的剂量优化及治疗药物监测(TDM)在高危住院患者中的应用有待进一步研究明确。

局限性

  • 纳入研究数量较少(5项队列研究),总样本量908例。
  • 部分研究未采用倾向评分匹配,可能存在混杂偏倚。
  • 替考拉宁在联合方案中的最佳剂量及TDM实施尚未明确,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Piperacillin-tazobactam combined with vancomycin is widely employed for broad-spectrum empiric coverage but has been increasingly associated with acute kidney injury (AKI). The comparative renal safety of substituting vancomycin with teicoplanin remains uncertain. OBJECTIVE: This meta-analysis aimed to evaluate renal outcomes between piperacillin-tazobactam plus teicoplanin (TZP-TEI) versus piperacillin-tazobactam plus vancomycin (TZP-VAN). METHODS: PubMed, Scopus, and Cochrane Central were searched for studies comparing TZP-TEI versus TZP-VAN in hospitalized patients. The primary outcome was AKI incidence, defined by Kidney disease: Improving global outcomes (KDIGO) or RIFLE (Risk of renal dysfunction, Injury to kidney, Failure or Loss of kidney function, and End-stage kidney disease) criteria. Data were analyzed using Review Manager, with heterogeneity assessed via the I2 statistic. RESULTS: A total of 908 patients were included from five cohort studies, four of which applied propensity-score matching (PSM), with reported ages ranging from 56.8 to 79 years. The TZP-TEI regimen was associated with a significantly reduced rate of AKI compared with TZP-VAN (odds ratio [OR] 0.52; 95% confidence interval [CI] 0.30-0.89; p = 0.02; I2 = 51%). No statistically significant differences were observed between groups for AKI recovery (OR 0.68; 95% CI 0.41-1.12; p = 0.13; I2 = 0%) or for 30-day all-cause mortality (OR 1.34; 95% CI 0.77-2.32; p = 0.30; I2 = 0%). Subgroup analyses stratified by AKI severity (KDIGO stages 1-3 or RIFLE criteria) demonstrated consistent directionality across stages, with no significant differences observed within PSM or non-PSM cohorts. CONCLUSION: The TZP-TEI combination was associated with a significantly lower incidence of AKI than was TZP-VAN. Further studies are warranted to validate these findings, optimize teicoplanin dosing within the TZP-TEI combination, and inform therapeutic drug monitoring implementation in high-risk hospitalized patients.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Mohammad S, Ghazal H, Rahimeh W, et al. Comparative Risk of Acute Kidney Injury with Piperacillin-Tazobactam Plus Teicoplanin Versus Piperacillin-Tazobactam Plus Vancomycin: A Systematic Review and Meta-Analysis. Drug Saf. 2025. PMID: 40940625. doi:10.1007/s40264-025-01611-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。